New trial
Phase 1 Study of BL-M17D1: HER2-directed mAb Auristatin (tubulin inhibitor) ADC
- Trial ID
- NCT06714617 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- First-in-human
- Location
- 12 Locations
- Published in
- New in Oncology - July 3, 2025
This Phase 1 open-label trial, sponsored by SystImmune Inc., assesses BL-M17D1 administered every three weeks in patients with HER2-expressing or HER2-mutated advanced/metastatic solid tumors. The study includes cohorts from urothelial, NSCLC, gastric, and gynecologic cancers to evaluate safety, tolerability, pharmacokinetics, and efficacy as monotherapy with dose escalation, dose finding, and expansion strategies.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings